

**Cengild Medical Berhad**

Registration No.: 202101004143 (1404442-P)  
(Incorporated in Malaysia)

**Unaudited Condensed Consolidated  
Interim Financial Report  
for the First Quarter Ended  
30 September 2025**

# Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

## Unaudited condensed consolidated statement of financial position as at 30 September 2025

	Note	Unaudited As at 30 September 2025 RM'000	Audited As at 30 June 2025 RM'000
<b>Assets</b>			
<b>Non-current assets</b>			
Investment in associates		3,679	3,374
Investment in joint ventures		32	26
Plant and equipment	A13	96,726	74,126
Right-of-use assets		1,311	1,498
Other receivable		439	607
Deferred tax assets		2,422	2,422
<b>Total non-current assets</b>		<b>104,609</b>	<b>82,053</b>
<b>Current assets</b>			
Inventories		2,034	2,045
Trade receivables		8,231	8,795
Other receivables, deposits and prepayments		2,210	3,158
Fixed deposits with licensed banks		79,925	72,641
Cash and bank balances		586	11,797
<b>Total current assets</b>		<b>92,986</b>	<b>98,436</b>
<b>Total assets</b>		<b>197,595</b>	<b>180,489</b>
<b>Equity</b>			
Share capital		87,487	87,487
Reserves		2,462	2,448
Retained profits		24,357	24,520
<b>Total equity</b>		<b>114,306</b>	<b>114,455</b>
<b>Liabilities</b>			
<b>Non-current liabilities</b>			
Loans and borrowings	B7	55,665	42,819
Lease liabilities	B8	1,820	2,415
Provision for restoration costs		754	746
<b>Total non-current liabilities</b>		<b>58,239</b>	<b>45,980</b>

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### Unaudited condensed consolidated statement of financial position as at 30 September 2025 (cont'd)

		Unaudited As at 30 September 2025 RM'000	Audited As at 30 June 2025 RM'000
	Note		
<b>Current liabilities</b>			
Trade payables		8,778	9,416
Other payables and accruals		9,059	6,490
Amount owing to directors		200	181
Lease liabilities	B8	2,340	2,316
Dividend payable		3,082	-
Current tax liabilities		1,591	1,651
<b>Total current liabilities</b>		<u>25,050</u>	<u>20,054</u>
<b>Total liabilities</b>		<u>83,289</u>	<u>66,034</u>
<b>Total equity and liabilities</b>		<u>197,595</u>	<u>180,489</u>

*The Unaudited Condensed Consolidated Statement of Financial Position should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.*

# Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

## Unaudited condensed consolidated statement of profit or loss and other comprehensive income for the first quarter ended 30 September 2025

	Note	Unaudited Individual/Cumulative quarter ended 30 September	
		2025	2024
		RM'000	RM'000
Revenue		18,669	22,210
Cost of sales		(10,090)	(11,939)
Gross profit		8,579	10,271
Other income		940	1,088
		9,519	11,359
Administrative expenses		(5,934)	(5,116)
Other expenses		(1)	-
Finance costs		(56)	(79)
<b>Profit from operations</b>		3,528	6,164
Share of profit of equity accounted associate		305	18
Share of profit of equity accounted joint ventures		7	7
<b>Profit before taxation</b>	B12	3,840	6,189
Income tax expense	B5	(922)	(1,655)
<b>Profit after taxation from Continuing Operations</b>		2,918	4,534
<b>Discontinued Operations</b>			
<b>Loss After Taxation from Discontinued Operations</b>	B13	-	(533)
Other comprehensive income		-	-
<b>Total comprehensive income for the financial period</b>		2,918	4,001
<b>Profit after taxation/Total comprehensive income for the financial period attributable to:-</b>			
<b>Owners of the Company:</b>			
- continuing operations		2,918	4,534
- discontinued operations		-	(533)
		2,918	4,001

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### Unaudited condensed consolidated statement of profit or loss and other comprehensive income for the first quarter ended 30 September 2025 (cont'd)

		Unaudited Individual/Cumulative quarter ended 30 September	
	Note	2025 RM'000	2024 RM'000
<b>Profit after taxation/Total comprehensive income for the financial period attributable to:-</b>			
<b>Owners of the Company:</b>			
- continuing operations		2,919	4,534
- discontinued operations		-	(533)
		<u>2,919</u>	<u>4,001</u>
<b>Earnings per ordinary share (sen)<sup>(1)</sup></b>			
Basic			
- continuing operations		0.35	0.54
- discontinued operations		-	(0.06)
		<u>0.35</u>	<u>(0.06)</u>
Diluted			
- continuing operations		0.35	0.54
- discontinued operations		-	(0.06)

<sup>(1)</sup> Earnings per ordinary share is calculated based on the weighted average number of ordinary shares referred to in Note B11.

*The Unaudited Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.*

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### Unaudited condensed consolidated statement of changes in equity for the first quarter ended 30 September 2025

	Share Capital RM'000	Reorganisation Reserve RM'000	Long Term Incentive Plan Reserve RM'000	Retained Profits RM'000	Total RM'000
<b>Unaudited</b>					
<b>At 1 July 2024</b>	87,487	1,530 <sup>(1)</sup>	737 <sup>(2)</sup>	21,543	111,297
Profit after taxation/Total comprehensive income for the financial period	-	-	-	4,001	4,001
<b>Contribution by and distributions to owners of the Company:</b>					
Share options to executives	-	-	45	-	45
Dividends to owners of the Company	-	-	-	(3,082)	(3,082)
<b>At 30 September 2024</b>	<u>87,487</u>	<u>1,530</u>	<u>782</u>	<u>22,462</u>	<u>112,261</u>

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### Unaudited condensed consolidated statement of changes in equity for the first quarter ended 30 September 2025 (cont'd)

	Share Capital RM'000	Reorganisation Reserve RM'000	Long Term Incentive Plan Reserve RM'000	Retained profits RM'000	Total RM'000
<b>Unaudited</b>					
<b>At 1 July 2025</b>	87,487	1,530 <sup>(1)</sup>	918 <sup>(2)</sup>	24,521	114,456
Profit after taxation/Total comprehensive income for the financial period	-	-	-	2,918	2,918
<b>Contribution by and distributions to owners of the Company:</b>					
Share options to executives	-	-	14	-	14
Dividends to owners of the Company	-	-	-	(3,082)	(3,082)
<b>At 30 September 2025</b>	<u>87,487</u>	<u>1,530</u>	<u>932</u>	<u>24,357</u>	<u>114,306</u>

<sup>(1)</sup> The reorganisation reserve represents the difference between the carrying value of the investment and the nominal value of shares of Cengild Sdn Bhd upon consolidation under the pooling-of-interests method of accounting.

<sup>(2)</sup> The share option reserves arise due to the Executive Share Option Scheme (ESOS) options granted on 15 April 2022.

The Unaudited Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

# Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

## Unaudited condensed consolidated statement of cash flows for the first quarter ended 30 September 2025

	Unaudited Individual/Cumulative quarter ended 30 September	
	2025 RM'000	2024 RM'000
<b>Cash flows from operating activities</b>		
<b>Profit before taxation</b>		
- continuing operations	3,840	6,189
- discontinued operations	-	(533)
<i>Adjustments for:</i>		
Depreciation of plant and equipment	1,226	1,200
Depreciation of right-of-use assets	187	336
Rent concessions	-	(17)
Interest expense	47	83
Unwinding of discount	9	7
Plant and equipment written off	1	-
Share options to executives	14	45
Share of net loss/(profit) of equity accounted associate	305	(18)
Share of profit of equity accounted joint venture	(7)	(7)
Interest income	(691)	(815)
<b>Operating profit before working capital changes</b>	<u>4,931</u>	<u>6,470</u>
Increase in inventories	11	(341)
Increase in trade and other receivables	1,680	(2,509)
Increase in trade and other payables	1,931	2,885
Increase in amount owing to directors	19	36
<b>Cash generated from operations</b>	<u>8,572</u>	<u>6,541</u>
Tax paid	<u>(982)</u>	<u>(1,035)</u>
<b>Net cash from operating activities</b>	<u>7,590</u>	<u>5,506</u>
<b>Cash flows (used in)/from investing activities</b>		
Interest received	691	815
Investment in an associate	(610)	(1,562)
Purchase of plant and equipment	(23,827)	(2,292)
Changes in deposits with tenure of more than 3 months	(5,851)	-
<b>Net cash (used in)/from investing activities</b>	<u>(29,597)</u>	<u>(3,039)</u>



## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### Unaudited condensed consolidated statement of cash flows for the first quarter ended 30 September 2025 (cont'd)

	<b>Unaudited Individual/Cumulative quarter ended 30 September</b>	
	<b>2025</b>	<b>2024</b>
	<b>RM'000</b>	<b>RM'000</b>
<b>Cash flows used in financing activities</b>		
Dividend paid	-	(3,082)
Interest paid	(47)	(83)
Repayment of lease liabilities	(571)	(576)
Drawdown of term loan	12,846	-
<b>Net cash used in financing activities</b>	<b>12,228</b>	<b>(3,741)</b>
<b>Net (decrease) /increase in cash and cash equivalents</b>	<b>(9,779)</b>	<b>(1,274)</b>
Cash and cash equivalents at the beginning of financial period	33,690	23,364
<b>Cash and cash equivalents at the end of financial period</b>	<b>23,911</b>	<b>22,090</b>

#### (i) Cash and cash equivalents

Cash and cash equivalents included in the consolidated statement of cash flows comprise the following consolidated statement of financial position amounts:

	<b>Unaudited Individual/Cumulative quarter ended 30 September</b>	
	<b>2025</b>	<b>2024</b>
	<b>RM'000</b>	<b>RM'000</b>
Cash and bank balances	586	2,351
Fixed deposits with licensed banks	79,925	85,913
	<b>80,511</b>	<b>88,264</b>
Pledged of bank balance	-	-
Deposits with tenure of more than 3 months	(56,600)	(66,174)
	<b>23,911</b>	<b>22,090</b>

The Unaudited Condensed Consolidated Statement of Cash Flows should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

# **Cengild Medical Berhad**

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

## **A. NOTES TO THE UNAUDITED CONSOLIDATED INTERIM FINANCIAL REPORT FOR THE FIRST QUARTER ENDED 30 SEPTEMBER 2025**

### **A1. Basis of preparation**

The condensed consolidated interim financial report is unaudited and has been prepared in accordance with the Malaysian Financial Reporting Standards ("MFRS") 134 Interim Financial Reporting and Paragraph 9.22 and Appendix 9B of the ACE Market Listing Requirements of Bursa Malaysia Securities Berhad ("Listing Requirements").

The condensed consolidated interim financial report should be read in conjunction with the Audited Financial Statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the condensed consolidated interim financial report.

### **A2. Significant accounting policies**

The accounting policies adopted by the Group in this interim financial report are the same as those applied by the Group in its audited consolidated financial statements for the financial year ended 30 June 2025 except for the adoption of those new Malaysian Financial Reporting Standards ("MFRS") and amendment to MFRS and Interpretations that are applicable to the Group for the financial period beginning 1 July 2025.

(a) As of 1 July 2025, the Group has adopted the following new accounting standards and/or interpretations (including the consequential amendments, if any).

MFRS and/or IC interpretations (including the consequential amendments):

- Amendments to MFRS 121: Lack of Exchangeability

The adoption of the above pronouncements did not have any material impact to the condensed consolidated interim financial report of the Group.

(b) The Group has not applied in advance the following accounting standard(s) and/or interpretation(s) (including the consequential amendments, if any) that have been issued by the Malaysian Accounting Standards Board (MASB) but are not yet effective for the current financial period:-

#### **Effective for financial periods beginning on or after 1 January 2026**

Amendments to MFRS 9 and MFRS 7: Amendments to the Classification and Measurement of Financial Instruments

Amendments to MFRS 9 and MFRS 7: Contracts Referencing Nature-dependent Electricity  
Annual Improvements to MFRS Accounting Standards—Volume 11

## **Cengild Medical Berhad**

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### **A2. Significant accounting policies (cont'd)**

**Effective for financial periods beginning on or after 1 January 2027**

MFRS 18 Presentation and Disclosure in Financial Statements

MFRS 19 Subsidiaries without Public Accountability: Disclosures

Amendments to MFRS 19: Subsidiaries without Public Accountability: Disclosures

**Effective date of these Standards have been deferred, and yet to be announced**

Amendments to MFRS 10 and MFRS 128: Sale or Contribution of Assets between an Investor and its Associate or Joint Venture

### **A3. Auditors' report**

The auditors issued an unqualified audit opinion on the audited consolidated financial statements for the financial year ended 30 June 2025.

### **A4. Seasonal or cyclical factors**

The nature of the Group's business was not subject to any significant seasonal and cyclical factors.

### **A5. Unusual item affecting Assets, Liabilities, Equity, Net Income or Cash Flows**

There were no material unusual items affecting assets, liabilities, equity, net income or cash flows during the current financial quarter under review.

### **A6. Material changes in accounting estimates**

There were no material changes in accounting estimates that have a material effect in the current financial quarter.

### **A7. Material events during the statement of financial position date**

There were no material events during the current financial quarter under review that have not been reflected in the condensed consolidated interim financial report.

### **A8. Material events subsequent to the statement of financial position date**

There were no material events subsequent to the end of the current financial quarter that have not been reflected in the condensed consolidated interim financial report.

## **Cengild Medical Berhad**

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### **A9. Material changes in the composition of the Group**

There were no changes in the composition of the Group for the current financial quarter under review.

### **A10. Debt and equity securities**

There were no other issuance, cancellations, repurchases, resale and repayments of debt and equity securities for the current financial quarter under review, except as disclosed in Note B7.

### **A11. Dividends paid**

There were no dividends paid during the current financial quarter under review.

### **A12. Operating segments**

No geographical segment information is presented as the Group's revenue and profit or loss are confined within Malaysia.

### **A13. Valuations of plant and equipment**

The Group does not adopt a revaluation policy on its plant and equipment. All plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses, if any.

### **A14. Contingencies**

There were no contingent assets and contingent liabilities as at the date of this condensed consolidated interim financial report.

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### A15. Related party transactions

#### Identities of related parties

For the purposes of this condensed consolidated interim financial report, parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control or jointly control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the parties are subject to common control. Related parties may be individuals or other entities.

Related parties also include key management personnel defined as those persons having authority and responsibility for planning, directing and controlling the activities of the Group either directly or indirectly and entity that provides key management personnel services to the Group. The key management personnel include all the Directors and certain members of senior management of the Group.

The Group has related party relationship with its Directors, associates, joint ventures and key management personnel and entities within the same group of companies.

#### Significant related party transactions

Significant related party transactions of the Group are as follows:

Transactions	Unaudited	
	Individual/Cumulative	
	quarter ended 30 September	
	2025	2024
	RM'000	RM'000
External consultancy fee contributed by directors	(70)	(80)
External consultancy fee contributed by other key management personnel	(52)	(56)
Anciliary services paid to a joint venture	14	3
Consultant fee paid to joint ventures	122	117
Hospital cost paid to joint ventures	49	56
Rental income charged to an associate	(40)	(34)
Management fee charged to an associate	(81)	(81)
Management fee charged joint ventures	(5)	(6)

### A16. Fair value information

There was no gain or loss arising from fair value changes of the Group's financial liabilities for the current quarter and financial period under review.

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### PART B - EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF ACE MARKET LISTING REQUIREMENT OF BURSA MALAYSIA SECURITIES BERHAD

#### B1. Review of financial performance

##### a) Review for the current financial quarter against preceding corresponding financial quarter

	Unaudited Individual quarter ended 30 September		
	2025 RM'000	2024 RM'000	Variance %
Revenue	18,669	22,210	(15.94)
Profit before taxation ("PBT")	<u>3,840</u>	<u>6,189</u>	(37.95)

The Group recorded revenue of RM18.67 million for the current financial quarter ended 30 September 2025, representing an decrease of approximately 15.94% as compared to the preceding corresponding financial quarter ended 30 September 2024 of RM22.21 million. The decrease is mainly due to admission census and number of surgeries performed for the current quarter.

The Group's PBT reduced by RM2.35 million or 37.95% mainly due to drop in revenue while fixed salary cost remain.

#### B2. Variation of results against preceding quarter

	Unaudited Individual quarter ended		
	September 2025 RM'000	June 2025 RM'000	Variance %
Revenue	18,669	19,481	(4.17)
PBT	<u>3,840</u>	<u>3,369</u>	13.98

The Group recorded revenue of RM18.67 million for the current quarter ended 30 September 2025, representing an drop of RM0.81 million or 4.17% as compared to the preceding quarter ended 30 June 2025 of RM19.48 million. The drop in revenue was mainly due to the lesser admission census and number of surgeries performed.

The Group's PBT increased by RM0.47 million or approximately 13.98% from RM3.37 million in the immediate preceding quarter to RM3.84 million in the current financial quarter.

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)  
(Incorporated in Malaysia)

### B3. Commentary on prospects

Given the performance of the Group 3-month financial period ended 30 September 2025, the Management believe that the census may rebound and the Group's prospects for the financial year ending 30 June 2026 remain favourable.

### B4. Profit forecast

Not applicable as the Group does not publish any profit forecast.

### B5. Income tax expense

Income tax expense comprises the following:

	<b>Unaudited</b>	
	<b>Individual/Cumulative</b>	
	<b>quarter ended 30 September</b>	
	<b>2025</b>	<b>2024</b>
	<b>RM'000</b>	<b>RM'000</b>
<i>Recognised in profit or loss</i>		
<b>Current financial period</b>		
Current tax expense	922	1,631
Deferred tax	-	24
	<u>922</u>	<u>1,655</u>
Effective tax rate	24.00%	26.74%

The effective tax rates of 24.00% for individual quarter ended 30 September 2025 was estimated as per the statutory tax rate.

Income tax expense in the form of provision is recognised based on management's estimate.

### B6. Status of corporate proposals announced

There is no any corporate proposal announced but not completed as at the date of this report.

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### B7. Loans and borrowings

Particulars of the Group's loans and borrowings are as follows:

	Note	Unaudited As at 30 September 2025 RM'000	Audited As at 30 June 2025 RM'000
<b>Non-current</b>			
Term loans - secured		55,665	42,819
		<u>55,665</u>	<u>42,819</u>
<b>Current</b>			
Term loans - secured		-	-
		<u>-</u>	<u>-</u>

The above borrowings are denominated in Ringgit Malaysia.

### B8. Lease liabilities

	Note	Unaudited As at 30 September 2025 RM'000	Audited As at 30 June 2025 RM'000
<b>Non-current</b>			
Lease liabilities	B8.1	1,820	2,415
		<u>1,820</u>	<u>2,415</u>
<b>Current</b>			
Lease liabilities	B8.1	2,340	2,316
		<u>2,340</u>	<u>2,316</u>

The above lease liabilities are denominated in Ringgit Malaysia.



## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### B8. Lease liabilities (cont'd)

#### B8.1 Lease liabilities

Lease liabilities are payable as follows:

	Future minimum lease payments RM'000	Interest RM'000	Present value of minimum lease payments RM'000
<b>Unaudited</b>			
<b>30.9.2025</b>			
Less than one year	2,286	123	2,163
Between one to five years	2,035	38	1,997
Over 5 years	-	-	-
	<u>4,321</u>	<u>161</u>	<u>4,160</u>
<b>Audited</b>			
<b>30.6.2025</b>			
Less than one year	2,470	154	2,316
Between one to five years	2,470	55	2,415
Over 5 years	-	-	-
	<u>4,940</u>	<u>209</u>	<u>4,731</u>

### B9. Material litigation

There are no material litigations as at the date of this report.

### B10. Dividends

There were no any dividends declared under the financial quarter under review.

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### B11. Earnings per ordinary share

The calculation of earnings per ordinary share at 30 September 2025 and 2024, was based on the profit attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding calculated as follows:

	<b>Unaudited Individual/Cumulative quarter ended 30 September</b>	
	<b>2025</b>	<b>2024</b>
Profit for the financial period attributable to owners of the Company (RM'000)		
- continuing operations	2,918	4,534
- discontinued operations	-	(533)
	<hr/>	<hr/>
Based on weighted average number of ordinary shares		
- basic ('000)	832,913 <sup>(1)</sup>	832,913 <sup>(2)</sup>
Effect of unexercised ESOS	-	-
	<hr/>	<hr/>
Adjusted weighted average number of ordinary shares ('000)	832,913	832,913
	<hr/>	<hr/>
Basic earnings per ordinary share (sen)		
- continuing operations	0.35	0.54
- discontinued operations	-	(0.06)
	<hr/>	<hr/>
Diluted earnings per ordinary share (sen)		
- continuing operations	0.35	0.54
- discontinued operations	-	(0.06)
	<hr/>	<hr/>

<sup>(1)</sup> Based on the weighted average number of issued share capital of 818,800,000 ordinary shares after the completion of the IPO, and with inclusion of number of ordinary shares from exercised ESOS and Special Issue shares.

<sup>(2)</sup> Based on the weighted average number of issued share capital of 818,800,000 ordinary shares after the completion of the IPO, and with inclusion of number of ordinary shares from exercised ESOS and Special Issue shares.

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### B12. Profit before taxation

	Unaudited Individual/Cumulative quarter ended 30 September	
	2025 RM'000	2024 RM'000
Profit before taxation is arrived at after charging/ (crediting):-		
Depreciation:		
- plant and equipment	1,226	1,200
- right-of-use assets	187	336
Rent concessions	-	(17)
Plant and equipment written off	1	-
Directors' remuneration	1,916	1,828
Staff costs:		
- short-term employee benefits	4,608	4,637
- defined contribution benefits	500	502
- LTIP expenses	9	30
Interest expense:		
- lease liabilities	47	83
- unwinding of discount	9	8
- others	-	-
Total interest income on financial assets measured at amortised cost	(691)	(815)

The Group did not report any provision for and write off of inventories, receivables, gain or loss on disposal of quoted or unquoted investments or properties, foreign exchange gain or loss and gain or loss on derivatives for the financial period under review.

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### B13. LOSS AFTER TAXATION FROM DISCONTINUED OPERATIONS

Impact of disposal of CGI Primary Care Sdn Bhd and it's subsidiaries during last financial year.

An analysis of the results of the discontinued operations is as follows:-

	<b>Unaudited</b>	
	<b>Individual/Cumulative quarter</b>	
	<b>ended 30 September</b>	
	<b>2025</b>	<b>2024</b>
	<b>RM'000</b>	<b>RM'000</b>
Profit or Loss		
Revenue	-	79
Cost of sales	-	(47)
Gross Profit	-	32
Other income	-	-
	-	32
Administrative expenses	-	(554)
Finance costs	-	(11)
Results from operating activities	-	(533)
Income tax expense	-	-
Results from operating activities, net of tax/Loss after taxation from discontinued operations	-	(533)

## Cengild Medical Berhad

Registration No.: 202101004143 (1404442-P)

(Incorporated in Malaysia)

### B14. Utilisation of proceeds

The status of the utilisation of proceeds raised from the IPO of RM72.20 million and the variation of the use of proceeds is as follows:

	(A)	(B)	(C) = (A) - (B)						
<u>Details of utilisation</u>	<u>Original intention for utilisation</u>	<u>Actual utilisation up to 29/12/2023</u>	<u>Balance of proceeds as at 29/12/2023</u>	<u>Variation</u>	<u>Balance of proceeds after variation</u>	<u>Actual utilisation from 29/12/2023 to 30/9/2025</u>	<u>Balance of proceeds as at 30/9/2025</u>	<u>Original timeframe for utilisation of proceeds</u>	<u>Revised timeframe for utilisation of proceeds</u>
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000		
Expansion of existing medical centre	13,000	3,092	9,908	(9,908)	-	-	-	Within 36 months from the Listing Date	-
Establishing new medical centres	37,100	-	37,100	(18,550)	18,550	-	18,550	Within 36 months from the Listing Date	-
Acquisition of new stratified property forming part of a purpose-built private medical centre	-	-	-	36,258	36,258	(36,258)	-	-	Within 36 months from the unconditional date of the sale and purchase agreement
Working capital	17,404	4,153	13,251	(7,800)	5,654 <sup>(1)</sup>	-	5,654	Within 24 months from the Listing Date	Within 36 months from the Listing Date
Defraying the listing expenses	4,700	4,497	203 <sup>(1)</sup>	-	-	-	-	Within 1 month from the Listing Date	
<b>Total</b>	<b>72,204</b>	<b>11,742</b>	<b>60,462</b>	<b>-</b>	<b>60,462</b>	<b>(36,258)</b>	<b>24,204</b>		

**Note:**

<sup>(1)</sup> The balance proceeds from listing expenses of RM203,000 will be re-allocated for working capital purposes.